The iCMLf April newsletter lands in inboxes today! If you didn't receive it, make sure you're signed up to our mailing list, and keep up to date with the latest news on CML and all things iCMLf buff.ly/49hjOG4 #CML #iCMLf #ChronicMyeloidLeukemia

Our April Newsletter will be dropping into your inbox within the next week. Make sure you're signed up to receive regular CML news and updates from the iCMLf. Sign up now: buff.ly/49hjOG4 📩 #CML #iCMLf #ChronicMyeloidLeukemia

We're looking forward to seeing those who signed up for the first South Asia Regional Discussion Group of 2024 today. It's not too late to join us - you can sign up here buff.ly/4citDpB See you there! #CML #iCMLf #ChronicMyeloidLeukemia #RegionalDiscussionGroups

Visit our invaluable resource – the Pediatric CML Module in the iCMLf Knowledge Centre. From understanding the nuances between Adult and Pediatric CML to navigating treatment recommendations - explore the module here: buff.ly/4bbHFI7 #CML #iCMLf #ChronicMyeloidLeukemia

Remember, the deadline for submitting your abstract for the John Goldman CML Meeting is approaching on May 8th. You can submit here: buff.ly/4aCCsZN @ESHaematology #eshcml2024 #CML #iCMLf #ChronicMyeloidLeukemia

Happy birthday to Brian J. Druker! He won a 2009 #LaskerAward for the development of molecularly-targeted treatments for #chronicmyeloidleukemia, converting a fatal cancer into a manageable chronic condition. @OHSUNews #NationalCancerControlMonth ow.ly/dqty30oehye

Ready to dive in? Visit the Knowledge Centre today: buff.ly/3SIm1ou 🌐 What's your favourite module? Let us know in the comments 👇 #CML #iCMLf #ChronicMyeloidLeukemia #KnowledgeCentre

Our March Papers of the Month, curated by Professor Tim Hughes, are now available. View the full list of papers via our website: buff.ly/4br0F6C 💬🔍 #CML #Chronicmyeloidleukemia #iCMLf #CMLResearch

Did you know that on the #iCMLf website we offer a wealth of information on #CML, including diagnosis, management, and valuable resources for patient support? Knowledge can be life-saving. Explore our patient resources at buff.ly/4aPh57O today. #ChronicMyeloidLeukemia

Are you following us on LinkedIn? Head over to LinkedIn and connect for the latest updates, resources, and opportunities to make a difference. Help us expand our network and our impact - you can find us here: buff.ly/3U3tDTb #CML #iCMLf #ChronicMyeloidLeukemia

We recognize the importance of early detection and diagnosis in #cancer care. Understanding the symptoms of #ChronicMyeloidLeukemia may lead to improved outcomes for people living with the condition. Learn more from @AmericanCancer: cancer.org/cancer/types/c…

At #ASCPT2024, see model-based pediatric dose recommendations from an ongoing BCR-ABL TKI phase 1/2 trial in patients with #ChronicMyeloidLeukemia PII-100 bit.ly/4ckOcBQ

Discover our article on Challenges and Considerations for Conducting Phase II #ChronicMyeloidLeukemia (CML) #ClinicalTrials Read more - bit.ly/3NNKXsv To learn more about our Phase II Trial Solutions write to us at [email protected] #Veeda #Leukemia #Phase2Trials

Have you checked out the #iCMLf Knowledge Centre recently? Our interactive, online resource is packed full of content developed by #CML experts from the iCMLf. Take a look today buff.ly/3SIm1ou #ChronicMyeloidLeukemia

Check your inbox for our brand new monthly Newsletter, arriving today. If you're not on our mailing list, sign up now and make sure you stay up to date with everything iCMLf! Sign up here: buff.ly/49hjOG4 #CML #iCMLf #ChronicMyeloidLeukemia

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial mediamedic.co/olverembatinib… #ChronicMyeloidLeukemia #Olverembatinib

Imatinib compared with second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase mediamedic.co/imatinib-compa… linkedin.com/feed/update/ur… #AmericanJournalofHematology #ChronicMyeloidLeukemia #CML

External Validation of Predictive Scoring Systems for Molecular Responses in Chronic Myeloid Leukemia Receiving Imatinib Therapy mediamedic.co/external-valid… linkedin.com/pulse/external… #ChronicMyeloidLeukemia #CML #hematologyresearch #Leukemiajournal